top of page


Italfarmaco licenses JCR's Phase III Hunter syndrome therapy JR-141 across US, Europe and Latin America
Italfarmaco has licensed JCR Pharmaceuticals' Phase III Hunter syndrome therapy JR-141 across the US, Europe and Latin America.

nuaxia
Oct 72 min read


Genentech licenses Alector brain-penetrant Parkinson's programme in deal worth up to $1.27bn
Genentech has licensed Alector's brain-penetrant AL050 programme in a neurodegeneration deal worth up to $1.27 billion.

nuaxia
Oct 62 min read
bottom of page